Fukuda Keiichi
Keio University School of Medicine , Cardiology Division, Department of Internal Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Future Cardiol. 2005 Mar;1(2):167-75. doi: 10.1517/14796678.1.2.167.
Recent studies have shown that cardiomyocytes can be induced to differentiate from several types of stem cells. Techniques to purify and transplant stem-cell-derived cardiomyocytes have also been developed, and the transplanted cells have been demonstrated to reside in the recipient hearts for long periods. Recently, cardiomyocyte cell sheets enabling transplantation of viable tissue have been reported. Promising results have also been obtained using cytokines to mobilize stem cells in vivo as a potential treatment for heart failure. However, a number of hurdles remain in the quest to treat heart failure by cell transplantation without the need for a donor at the preclinical stage. In the next phase, the field needs to develop innovations to specifically differentiate cardiomyocytes from stem cells, to purify cardiomyocytes from contaminating cells in a cell mixture using a high-throughput method, and to establish and maintain artificial regenerated tissue using tissue engineering for transplantation.
最近的研究表明，几种类型的干细胞可被诱导分化为心肌细胞。纯化和移植干细胞来源的心肌细胞的技术也已得到发展，并且已证明移植的细胞可在受体心脏中长期存在。最近，已有关于能够移植活组织的心肌细胞片的报道。使用细胞因子在体内动员干细胞作为心力衰竭的潜在治疗方法也取得了有前景的结果。然而，在临床前阶段，通过细胞移植治疗心力衰竭而无需供体的探索中仍存在许多障碍。在下一阶段，该领域需要进行创新，以从干细胞中特异性分化心肌细胞，使用高通量方法从细胞混合物中的污染细胞中纯化心肌细胞，并使用组织工程建立和维持用于移植的人工再生组织。
